THE AMERICAN ASSOCIATION of
AACE Annual Scientific

CLINICAL ENDOCRINOLOGISTS
& Clinical Congress

Congress Program Agenda with Educational Objectives

WEDNESDAY, May 25

6:30 am – 6:30 pm

Registration

12:30 pm – 6:30 pm

CME Station Hours

8:00 am – 12:00 pm

Pre Congress Session I

 

W11: Diabetes Technology 2016
Chair: George Grunberger, MD

  • Update on Insulin Pump Therapy and Continuous Glucose Monitoring
    Bruce W. Bode, MD

Room: Suwannee 16/17
CME Code: 5223

 

W21: Inpatient Endocrinology Part 1: Diabetes and Nutrition
Chair: Etie S. Moghissi, MD; S. Sethu Reddy, MD

Room: Suwannee 11/12
CME Code: 7518

 

W31: Cardiovascular Medicine for the Endocrinologist
Chair: Chris K. Guerin, MD

Room: Suwannee 18/19
CME Code: 7631

 

W41: Comprehensive Approach to Clinical Thyroidology
Chair: Mark Lupo, MD

Room: Suwanee 20/21
CME Code: 6256

1:00 pm – 5:00 pm

W12: Inpatient Endocrinology Part 2: What an Endocrinologist Needs to Know About Surgery and What a Surgeon Needs to Know About Endocrinology
Chair: Mira Milas, MD;& Jeffrey Garber, MD
Thyroid and Parathyroid Session

  • Case-based Panel Discussion

Pituitary and Adrenal Session

  • Case-based Panel Discussion

 

W22: The Practice of Obesity Medicine in 2016
Chair: J. Michael Gonzalez-Campoy, MD, PhD

 

W32: Bone Disease in 2016: Beyond the Basics
Co-Chairs: Daniel L. Hurley, MD; Rachel Pessah-Pollack, MD

 

W42: AACE – ABIM Maintenance of Certification and Mini - Board Review Course
Chair: Pauline M. Camacho, MD
Speakers: Pauline Camacho, MD; Elise Brett, M; Hossein Gharib, MD; Dace Trence, MD

  • Endocrinology Update 2015
  • Endocrinology Update 2016

5:30 pm – 7:45 pm

WSS1: Hypoparathyroidism: New Treatment Concepts & Guidelines

5:30 pm – 7:45 pm

WSS2: Concentrated Insulins: Clinical Applications and Use in Practice Settings

THURSDAY, MAY 26

5:15 am – 7:30 am

TSS1: LDL-C Reduction in the Patient with Diabetes: How Low Should We Go and How Should We Get There?
Room: Panzacola H 1/2
CME Code: 1575

6:30 am – 6:30 pm

Registration

7:00 am – 6:00 pm

CME Station Hours

9:45 am -2:15 pm

Exhibit Hall Hours

8:00 am – 8:30 am

General Session Announcements

8:30 am – 9:15 am

TGS1: Diabetes and the Microbiome
Moderator: George Grunberger, MD
Speaker: Robert E. Ratner, MD

Room: Panzacola F/G
CME Code: 5331

9:15 am – 10:00 am

TGS2: Metabolomics for the Clinician: Implications for the Treatment of Metabolic Disease
Moderator: Derek LeRoith, MD
Speaker: Christopher B. Newgard, PhD

Room: Panzacola F/G
CME Code: 8024

10:00 am – 11:00 am

Young Investigator Poster Session in Exhibit Hall

10:15 am – 11:00 am

Product Theaters in the Exhibit Hall

11:15 am – 12:00 pm

TGS3: Co-Evolution of Scientific Disciplines and Therapies for Disorders of Lipid Metabolism
Moderator: Jonathan D. Leffert, MD
Speaker: Jay D. Horton, MD

Room: Panzacola F/G
CME Code: 2893

12:00 pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00 pm – 12:45 pm

Young Investigator ePoster Oral Presentations

12:30 pm – 2:15 pm

Women of Endocrinology Luncheon
Lessons in Leadership: My Path to Presidency (Non-CME)

Moderator: Etie S. Moghissi, MD
Speaker: Pauline M. Camacho, MD

1:00 pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm – 2:00 pm

Product Theaters in the Exhibit Hall

2:15 pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

T11: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael D. Holick, MD

Room: Suwannee 16/17
CME Code: 8253

 

T21: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time Versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: Richard E. Pratley, MD vs. Alan J. Garber, MD
Room: Suwannee 11/12
CME Code: 7548

 

T31: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, MD

Room: Suwannee 13/14
CME Code: 4915

 

T41: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

Room: St. John's 24/25
CME Code: 1886

 

T51: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: William D. Zigrang, MD
Speaker: William F. Young Jr., MD

Room: St. John's 28/29
CME Code: 1354

 

T61: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

Handout:1
Handout:2

Room: Suwannee 20/21
CME Code: 3145

 

T71: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: Farhad Zangeneh, MD
Speaker: Michael McDermott, MD

Room: Suwannee 18/19
CME Code: 7336

3:15 pm – 3:30 pm Coffee Break
3:30 pm – 4:30 pm MEET-THE-EXPERTS SESSION II
 

T12: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Handout

Moderator: M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

Room: Suwannee 15
CME Code: 9554

 

T22: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That Is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth Ain, MD vs. Ian Hay, MD

Room: Suwannee 16/17
CME Code: 1959

 

T32: Is Insulin Therapy Inevitable in the Management of Diabetes?
Moderator: Vivian Fonseca, MD
Speaker: Robert E. Ratner, MD

Room: Suwannee 20/21
CME Code: 7264

 

T42: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, MD

Room: Suwannee 13/14
CME Code: 5304

 

T52: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

Room: St. John's 24/25
CME Code: 9533

 

T62: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: Farhad Zanganeh, MD
Speaker: William F. Young Jr., MD

Room: St. John's 28/29
CME Code: 2042

 

T72: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: William D. Zigrang, MD
Speaker: Michael McDermott, MD

Room: Suwannee 18/19
CME Code: 4068

4:30 pm – 4:45 pm Break
4:45 pm – 5:45 pm MEET-THE-EXPERTS SESSION III
 

T13: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael F. Holick, MD

Room: St. John's 24/25
CME Code: 3847

 

T23: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: Richard E. Pratley, MD vs. Alan J. Garber, MD

Room: Suwannee 11/12
CME Code: 8878

 

T33: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

Room: Suwannee 18/19
CME Code: 8156

 

T43: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Handout

Moderator:M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

Room: Suwannee 15
CME Code: 4926

 

T53: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth Ain, MD vs. Ian Hay, MD

Room: Suwannee 16/17
CME Code: 9985

 

T63: Is Insulin Therapy Inevitable in Management of Diabetes?
Moderator: George Grunberger, MD
Speaker: Robert E. Ratner, MD

Room: Suwannee 20/21
CME Code: 7406

 

T73: History of Diabetes Mellitus: 1500 B.C. to Present
Moderator: Chris K. Guerin, MD
Speaker: Philip Levy, MD

Room: Suwannee 13/14
CME Code: 1465

6:00 pm – 7:00 pm Domestic & International Chapter Receptions
7:15 pm – 9:30 pm

TSS3: Balancing the Evidence: Considering the Clinical Impact of Newer Antihyperglycemic Agents for the Treatment of Type 2 Diabetes

Room: Panzacola H 3/4
CME Code: 1284

 

TSS4: Patient Centered Care of the Patient with Obesity

Room: Panzacola H 1/2
CME Code: 1304

FRIDAY, MAY 27

5:15am – 7:30 am

FSS1: Keeping Pace with CGM Technology: The Path to Successful Implementation
Room: Panzacola H 1/2
CME Code: 3374

7:30am – 6:30 pm

Registration

7:30am – 6:30 pm

CME Station Hours

9:45am – 2:15 pm

Exhibit Hall Hours

8:00am – 8:20 am

General Session Announcements

8:20am – 9:05 am

FGS1:Pheochromocytoma: Then and Now - A 90-Year Journey
Moderator: Daniel L.Hurley, MD
Speaker: William F.Young Jr., MD

Room: Panzacola F/G
CME Code: 7835

9:15am – 12:00 pm

IN-DEPTH SYMPOSIA SESSION I
MOC Points will beavailable for select In-Depth Symposia

 

F11: Thryoid Cancer Update
Chair: Hossein Gharib, MD
Supported by the Hossein Gharib, MD Educational Fund

  • Radioactive Iodine Treatment inThyroid Cancer
    Gregory A. Wiseman, MD

Room: Panzacola H 3/4
CME Code: 1412

 

F21: Endocrine Disorders during Pregnancy
Chair: Felice A.Caldarella, MD

Room: Suwannee 13/14
CME Code: 8929

 

F31: AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
Chair: W. Timothy Garvey, MD

  • Benefits of Weight Loss Treatment
    Ania Jastreboff, MD

Room: St. John's 24/25
CME Code: 7583

 

F41: Diabetes Update 2016
Chair: Robert R. Henry, MD

 

F51: Practical Clinical Guide to Endocrine Diseases for Nurse Practitioners/ Physician Assistants
Chairs: W. Reid Litchfield, MD; Sondra O’ Callaghan, PA

 

F61: Novel Developments in Diabetes Technology (Non-CME)
Moderators: Timothy Bailey, MD; Alan Garber, MD; R. Mack Harrell, MD

Room: Suwannee 18/19

12:00pm – 2:15 pm

Exhibit Hall Break

12:00pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00pm – 12:45 pm

ePoster Oral Presentations

12:30pm – 2:15 pm

FIT Luncheon

1:00pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm– 2:00 pm

Product Theaters in the Exhibit Hall

2:15pm – 5:00 pm

IN-DEPTH SYMPOSIASESSION II
MOC Points will beavailable for select In-Depth Symposia

 

F12: A Tributeto Saul Hertz: 75th Anniversary of the Use of Radioactive Iodine
Chair: Jeffrey R.Garber, MD; Lewis E. Braverman, MD

  • The Sodium/Iodide Symporter (NIS): From Patient to Molecule and Back
    Nancy Carrasco, MD
  • Targeted Approaches for Enhancing RAI Avidity in Thyroid Cancer
    Alan Ho, MD

Room: Suwannee 15
CME Code: 9758

 

F22: TransgenderMedicine: What an Endocrinologist Should Know
Chair: Vin Tangpricha, MD

Room: Suwannee 11/12
CME Code: 9137

 

F32: Endocrinology and Aging, or, “The Taper”
Chair: Peter A. Singer, MD

Room: Panzacola H 3/4
CME Code: 2266

 

F42: Neuroendocrine Tumor (NET) Syndromes
Chair: Aaron I. Vinik, MD

Room: Suwannee 16/17
CME Code: 1040

 

F52: 8th AACE/SMNE Joint Session: Reflections and Future Directions in Endocrinology
(presented in Spanish)
Co-Chairs: Myriam Allende-Vigo, MD & Miguel A.Madero, MD

Room: Suwannee 18/19
CME Code: 9910

 

F62: The Future of Endocrinology Reimbursement
Co-Chairs: Katherine Roberts, MD; Howard Lando, MD

  • Creating a New Business Model For Endocrinology: The ACO and the Endocrinologist
    William Biggs, MD
  • Informatics 2016: How Do We Get from Meaningful Use to Precision Medicine?
    Douglas Fridsma, MD

Room: Suwannee 20/21
CME Code: 1073

5:00pm – 6:15 pm

Poster Session in Exhibit Hall

5:00pm – 6:30 pm

Wine & Cheese Reception in Exhibit Hall

6:15pm – 7:00 pm

Product Theaters in the Exhibit Hall

7:00pm – 9:15 pm

FSS3: Basal Insulin 4.0: Updating Your Clinical Practice with Ultralong-acting Insulins

Room: Panzacola H 1/2
CME Code: 6224

7:00pm – 9:15 pm

FSS4: Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options

Room: Panzacola H 3/4
CME Code: 1809

SATURDAY, MAY 28

7:30am – 5:00 pm

Registration

7:00am – 6:00 pm

CME Station Hours

9:45am -2:15 pm

Exhibit Hall Hours

8:00am – 8:15 am

Award Presentations

8:15am – 9:00 am

SGS1: The Role of Molecular Markers in Thyroid Nodule Management: Then and Now
Moderator: Hossein Gharib, MD
Speaker:Yuri Nikiforov, MD
Room: Panzacola F/G
CME Code: 3245

9:00am – 9:15 am

Award Presentations

9:15am – 10:00 am

SGS2: The Obesity Epidemic, A Public Health Emergency?
Moderator:Yank Coble, MD
Speaker: Regina Benjamin, MD
Room: Panzacola F/G
CME Code: 3103

 

SGS3: Select Abstract Oral Presentations I
Moderator: S. Sethu Reddy, MD

THE PREVALENCE OF FASTING-EVOKED EN-ROUTE HYPOGLYCEMIA IN DIABETES (FEEHD) IN CLINICAL PRACTICE: A PILOTSURVEY
Saleh Aldasouqi, MD

CONTEMPLATING AN ADDITIONAL ORAL AGENTFOR YOUR PATIENT WITH TYPE 2 DIABETES? CONSIDER POSSIBLE INTERACTION BETWEENQUALITY OF YOUR CONVERSATION WITH PATIENT’S ATTEMPTS AT BARGAINING ANDSELF-REPORTED OUTCOMES - LESSONS FROM THE INTRODIA™ STUDY
Leo Seman, MD

A RANDOMIZED CONTROL TRIAL ON REDUCTIONOF HEMOGLOBIN A1C USING CELL PHONES, COMMUNITY HEALTH WORKERS OR COMBINATIONOF BOTH IN A DISTRICT OF COLUMBIA AFRICAN AMERICAN POPULATION
Nesreen Hagahmed, MBBS

Room: Panzacola H 1/2
CME Code: 6849

 

SGS4: Select Abstract Oral Presentations II
Moderator: David Lieb, MD

SYSTEMATIC REVIEW OF THE POSITIVE PREDICTIVE VALUE OF RAS MUTATIONSIN CYTOLOGICALLY INDETERMINATE THYROID NODULES
Mark Lupo, MD

RADIO FREQUENCY ABLATION: AN INNOVATIVE TREATMENT FORADRENAL NEOPLASMS
Lima Lawrence, MD

USE OF A DIGITAL HEALTH OFFERING TO OPTIMIZE STATIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES
Juan Frias, MD, FACE

Room: Panzacola H 3/4
CME Code: 8071

10:00am – 11:00 am

Late Breaking Poster Session in Exhibit Hall

10:15am – 11:00 am

Product Theaters in the Exhibit Hall

11:00am – 11:15 am

Award Presentations

11:15am – 12:00 pm

SGS5: Osteoporosis Drugs: Then and Now
Moderator: Pauline M. Camacho, MD
Speaker: Michael R. McClung, MD

Room: Panzacola F/G
CME Code: 4744

11:15am – 12:15 pm

SGS6: Late Breaking Oral Presentations (Non-CME)
Moderators: S. Sethu Reddy, MD; David C. Lieb, MD

Room: Panzacola H 1/2

12:15pm – 2:00 pm

AACE Annual Business Meeting Luncheon

2:15pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

S11: Treatment of Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy, MD

Room: Suwannee 20/21
CME Code: 1741

 

S21: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Ved V.Gossain, MD
Speaker: Henry G. Bone III, MD

Room: St. John's 28/29
CME Code: 1429

 

S31: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator: Kathleen Wyne, MD
Speaker: S. Mitchell Harman, MD

Room: Suwannee 16/17
CME Code: 3734

 

S41: Diagnosis and Management of Anabolic Steroid Abuse

Slides PDF
Moderator: Sri Prakash Mokshagundam, MD
Speaker: Darius A. Paduch, MD

Room: Suwannee 15
CME Code: 8320

 

S51: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Sandra L.Weber, MD
Speaker: Stephanie Lee, MD

Room: St John's 24/25
CME Code: 6429

 

S61: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A.Trager,MD
Speaker: Juan P. Brito,MD

Room: Suwannee 13/14
CME Code: 1901

 

S71: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S.H.Bell, MD
Speaker: Joseph G.Verbalis, MD

Room: Suwannee 11/12
CME Code: 2819

 

S81: Approach to the Transgender Adolescent: The Evaluation
Moderator: Vin Tangpricha, MD
Speaker: Stephen M. Rosenthal, MD

Room: Suwannee 18/19
CME Code: 3838

3:15pm– 3:30pm

Coffee Break

3:30pm – 4:30 pm

MEET-THE-EXPERTS SESSION II

 

S12: Challenging Pituitary Cases
Moderator: Anne L. Leddy, MD
Speaker: Eliza B. Geer,MD

Room: Suwannee 16/17
CME Code: 4222

 

S22: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Dace Trence,MD
Speaker: Bart L.Clarke, MD

Room: Suwanee 20/21
CME Code: 4887

 

S32: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD; Vin Tangpricha,MD
Case Study: The Jennings Family (“I am Jazz”)
Room: Suwannee 18/19
CME Code: 4907

 

S42: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A.Trager, MD
Speaker: Juan P. Brito,MD

Room: Suwannee 13/14
CME Code: 9250

 

S52: Diagnosis and Management of Anabolic Steroid Abuse

Slides PDF
Moderator: Sri Prakash Mokshagundam,MD
Speaker: Darius Paduch, MD

Room: Suwannee 15
CME Code: 7699

 

S62: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Elise Brett, MD
Speaker: Stephanie Lee, MD

Room: St. John's 24/25
CME Code: 3718

 

S72: Osteoporosis Drug Holidays: Why, When and What's After
Moderator: Victor L. Roberts, MD
Speaker: Paul D. Miller, MD

Room: St. John's 28/29
CME Code: 4714

 

S82: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S. H. Bell, MD
Speaker: Joseph G. Verbalis, MD

Room: Suwannee 11/12
CME Code: 5867

4:30pm – 4:45 pm

Break

4:45pm – 5:45 pm

MEET-THE-EXPERTS SESSION III

 

S13: Treatmentof Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy,MD

Room: Suwannee 15
CME Code: 9405

 

S23: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator: Rhoda H.Cobin, MD
Speaker: S. Mitchell Harman, MD

Room: St. John's 24/25
CME Code: 9365

 

S33: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Gary W. Edelson, MD
Speaker: Henry G. Bone III, MD

Room: Suwannee 11/12
CME Code: 1235

 

S43: Challenging Pituitary Cases
Moderator: Alex Tessnow, MD
Speaker: Eliza Geer, MD

Room: Suwannee 16/17
CME Code: 7716

 

S53: Osteoporosis - Drug Holidays: Why, When and What's After
Moderator: Paul V.Tomasic, MD
Speaker: Paul D. Miller, MD

Room: St. John's 28/29
CME Code: 6711

 

S63: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Donald A. Bergman, MD
Speaker: Bart L. Clarke, MD

Room: Suwannee 20/21
CME Code: 9542

 

S73: Medicine After the Holocaust
Moderator: Richard S. Rosenthal, MD
Speaker: Sheldon Rubenfeld, MD

Room: Suwannee 13/14
CME Code: 9817

 

S83: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD
Case Study: The Jennings Family (“I am Jazz”)

Room: Suwannee 18/19
CME Code: 9648

6:30pm

ACE Convocation

7:30pm

President’s Gala

SUNDAY, MAY 29

7:00 am – 11:00 am

Registration

7:00 am - 8:00 am

Attendee Breakfast
Room: Panzacola F/G

7:30 am – 12:00 pm

CME Station Hours

8:00 am – 8:15 am

General Session Announcements

8:15 am – 8:45 am

SGS8: Controversies in the Approach to Adrenal Nodules
Moderator: Antonia E. Stephen, MD
Panel: Karel Pacak, MD, Antonia E. Stephen, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 7017

8:45 am – 9:30 am

SGS9: The Mystery of the Hidden Parathyroid Adenoma
Moderator: Jennifer L. Marti, MD
Panel: Azeez Farooki, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 5418

9:30 am – 9:45 am

Coffee Break

9:45 am – 11:00 am

SGS7: Dilemmas in Thyroid Cancer: Endocrine/Surgical Consensus
Moderator: Gregory W. Randolph, MD
Speaker: Peter A. Singer, MD, Gregory W. Randolph, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 1043

11:00 am – 11:15 am

Final Announcements; Adjournment

WEDNESDAY, May 25

6:30 am – 6:30 pm

Registration

12:30 pm – 6:30 pm

CME Station Hours

8:00 am – 12:00 pm

Pre Congress Session I

 

W11: Diabetes Technology 2016
Chair: George Grunberger, MD

  • Update on Insulin Pump Therapy and Continuous Glucose Monitoring
    Bruce W. Bode, MD
  • Initiating and Interpreting Meter/Pump/Sensor Downloads in Your Practice: Case Studies
    Irl B. Hirsch, MD
  • Automated Predictive Low Glucose Management in Practice: Early Clinical Experience
    Martin Prazny, MD
  • Role of Diabetes Technologies in Advancing Diabetes Care
    Satish K. Garg, MD
  • Advances Towards the Bionic Pancreas
    Ron Brazg, MD

EDUCATIONAL OBJECTIVES:

  • Describe the indications and risks of Insulin Pump Therapy
  • Be able to state the benefits and indications of Sensor-Augmented Therapy
  • List the indication for CGM

EDUCATIONAL OBJECTIVES:

  • Understand the basic principles of statistical analysis of glucose meter and sensor downloads
  • Review translation of pump data downloads into changes in behavior
  • Review how trend changes in CGM can alter insulin and/or food decisions.

EDUCATIONAL OBJECTIVES:

  • Recognize the advantages and limitations of predictive insulin suspension and resume in sensor augmented pump users.
  • Identify the critical points in patients´ education based on the data from pump and sensor.
  • Arrange therapeutic plans for diabetic patients treated with modern insulin pumps.

EDUCATIONAL OBJECTIVES:

  • Upcoming Technologies-review
  • Role peer-review journals in accepting technologies in clinical care
  • Hurdles in implementation

EDUCATIONAL OBJECTIVES:

  • Identify the components of an artificial pancreas device system
  • Understand the complexities in developing a closed loop system
  • Review the iterations in the development of a functional hybrid closed loop system

Room: Suwannee 16/17
CME Code: 5223

 

W21: Inpatient Endocrinology Part 1: Diabetes and Nutrition
Chair: Etie S. Moghissi, MD; S. Sethu Reddy, MD

  • Glycemic Management: From Bedside to the Cloud
    S. Sethu Reddy, MD
  • Approaches to Glycemic Management in the Hospital: ICU and Beyond
    Guillermo Umpierrez, MD
  • ICU to Floor to Home: Modern Approaches to Transition of Care
    Etie S. Moghissi, MD
  • Improved Inpatient Glucose Management: Demonstrating the Value to Both Patients and Hospitals
    Osama Hamdy, MD

EDUCATIONAL OBJECTIVES:

  • Explain relevance of recent in-patient glycemic management publications
  • Incorporate best practices into one's local environment
  • Recognize the benefits of connectivity to achieve better outcomes

EDUCATIONAL OBJECTIVES:

  • Develop a consistent approach to initiating subcutaneous insulin after ICU care
  • Make appropriate adjustments in subcutaneous insulin therapy to accommodate special situations in hospitalized patients with hyperglycemia.
  • Discuss advances on non-insulin agents for the management of hyperglycemia in the hospital setting
  • Discuss strategies tailor transition of care from hospital to home using HbA1c value.

EDUCATIONAL OBJECTIVES:

  • Develop a consistent approaches to safe and effective handoffs between providers
  • Develop an standard protocol to transition patients from IV to SC insulin in a safe and effective manner
  • Discuss effective and safe strategies during preoperative transition
  • Discuss strategies to tailor transition of care from hospital to the outpatient setting

EDUCATIONAL OBJECTIVES:

  • Learn about the health-economic impact of managing diabetes by a specialized diabetes team versus diabetes management by primary service team and hospitalists
  • Demonstrate the impact of using a proper diabetes nutrition during hospitalization on the length of stay and total hospital cost
  • Discuss the opportunity of healthcare cost saving by managing mild and moderate cases of diabetic ketoacidosis in the emergency department (EVADE program)

Room: Suwanee 11/12
CME Code: 7518

 

W31: Cardiovascular Medicine for the Endocrinologist
Chair: Chris Guerin, MD

  • Endocrinologists as Hypertension Specialists
    Naomi D.L. Fisher, MD
  • Updates in Lipid Management
    Sergio Fazio, MD
  • Incorporating Metabolism Into the Endocrinologist’s Practice
    Yehuda Handelsman, MD
  • Dietary Strategies for Improving Cardiovascular Health
    Jeffrey I. Mechanick, MD

EDUCATIONAL OBJECTIVES:

  • Understand the scope and ramifications of the syndrome of hypertension, and describe the most effective diagnostic pathways
  • Drug choices and BP goals: understand the competing guidelines and algorithms to provide best treatment
  • Secondary hypertension: explain this widening category; be able to implement updated evaluation and treatment strategies

EDUCATIONAL OBJECTIVES:

  • Describe standard care lipid management vis a vi competing and discordant guidelines
  • Predict and position role of novel agents in the management of severe hypercholesterolemia
  • Define CVD risk assessment strategies

EDUCATIONAL OBJECTIVES:

  • Be aware of the advantage- for the patient and the endocrinologist- in providing comprehensive care, addressing Hyperglycemia,HTN, Dyslipidemia, Coagulation and Obesity in the prevention and management atherosclerosis Cardiovascular disease
  • Be familiar with available in office procedures to improve efficiency and income: Xray- chest, EKG, Treadmill Stress Test,Vascular Ultrasound- Carotid, Aorta, Renal Artery, Peripheral arterial and Veins studies. Echo cardiogram & StressEchocardiogram. Sleep studies, 24 hrs BP monitor. Holter M.
  • Be Educated of available studies & procedures: C/T & EBCT calcium scoring, Multislice CT scan I.V. angiogram, MR Coronaries (as become available), advanced lipid testing, Lipid Clinic, Bariatric Surgery, Dietary-Nutrition-education support and/orindependent.

EDUCATIONAL OBJECTIVES:

  • To be familiar with basic aspects of molecular nutrition, particularly as they apply to cardiometabolic risk reduction
  • To be able to discuss various popular diets and supplements and how they may be harmful or helpful to each patient (please include Paleo, Ornish, Vegan, etc)
  • To be able to design an set of specific nutritional recommendations for an individual patient based on their cardiometabolic risk profile

Room: Suwannee 18/19
CME Code: 7631

 

W41: Comprehensive Approach to Clinical Thyroidology
Chair: Mark A. Lupo, MD

  • Recognizing Ultrasound Patterns in the Assessment of Thyroid Nodules
    Mark A. Lupo, MD
  • Working with Your Cytopathologist to Improve Diagnostic Accuracy
    Zubair Baloch, MD
  • Incorporating Nuclear Medicine Into an Endocrine Office
    J. Anthony Parker, MD
  • Overcoming the Socioeconomic Challenges in a Thyroidology Practice
    Ryan Hungerford, MD

EDUCATIONAL OBJECTIVES:

  • Recognize ultrasound features of low risk and high risk thyroid nodules
  • Understand the different types of echogenic foci commonly seen in thyroid ultrasound
  • Highlight the importance of pattern recognition during physician performed neck ultrasound

EDUCATIONAL OBJECTIVES:

  • Discuss the value of cytologic-histologic correlation for continuous quality improvement of practice.
  • Review the current status of thyroid FNA and challenging aspects of the Bethesda System.
  • Discuss how clinical and imaging data may enhance the cytopathologic diagnosis

EDUCATIONAL OBJECTIVES:

  • Diagnose subacute thyroiditis, autonomous nodule, and Graves' disease in hyperthyroid patients using a thyroid scan.
  • Recognize normal variants on whole body scans obtained post radioactive iodine therapy.
  • Recognize common patterns of metastatic disease on whole body scans obtained post radioactive iodine therapy.

EDUCATIONAL OBJECTIVES:

  • Identify components of a successful thyroid-emphasis medical practice
  • Review billing and coding topics related to thyroid sonography and US-guided procedures
  • Identify value of ENCU designation and certification

Room: Suwannee 20/21
CME Code: 6256

1:00 pm – 5:00 pm

W12: Inpatient Endocrinology Part 2: What an Endocrinologist Needs to Know About Surgery and What a Surgeon Needs to Know About Endocrinology
Chair: Mira Milas, MD; Jeffrey Garber, MD
Thyroid and Parathyroid Session

  • Thyroid and Parathyroid Surgery
    Antonia Stephen, MD
  • Thyroid and Parathyroid Perioperative Endocrinology
    Sathya G. Jyothinagaram, MD
  • Case-based Panel Discussion

Pituitary and Adrenal Session Pituitary and Adrenal Perioperative Endocrinology
Maria Fleseriu, MD

  • Pituitary Surgery
    Edward R. Laws, MD
  • Adrenal Surgery
    Daniel Ruan, MD
  • Case-based Panel Discussion

EDUCATIONAL OBJECTIVES:

  • Understand the office evaluation for a thyroid surgical patient
  • Introduce the surgical decision making and approaches to thyroidectomy
  • Review the pre-operative localization studies and surgical approach in hyperparathyroidism

EDUCATIONAL OBJECTIVES:

  • Review Pre-operative management of Thyroid disease
  • Review Post-operative management and long term surveillance of thyroid cancer
  • Review Post-operative management of Parathyroid disease

EDUCATIONAL OBJECTIVES:

  • Recognize the morbidity associated with hypopituitarism before pituitary surgery
  • Review therapeutic options for treatment of hormonal dysfunction in the immediate period after pituitary surgery
  • Review hormonal work-up for patients with adrenal tumors undergoing adrenal surgery

EDUCATIONAL OBJECTIVES

  • Describe the preoperative laboratory assessment of pituitary function
  • Evaluate potential problems with surgical and anesthesia management of patient with Acromegaly
  • Identify the situations where cortisol replacement is necessary to cover the risks of surgery and anesthesia

EDUCATIONAL OBJECTIVES:

  • Understand the indications for adrenalectomy
  • List the potential complications of adrenal surgery
  • Describe the various conventional and minimally invasive approaches to adrenalectomy

Room: Suwannee 11/12
CME Code: 5282

 

W22: The Practice of Obesity Medicine in 2016
Chair: J. Michael Gonzalez-Campoy, MD

  • Guidelines for the Management of Obesity as an Endocrine Disease
    W. Timothy Garvey, MD
  • Designing a Successful Obesity Medicine Practice
    Elena A. Christofides, MD
  • From Behavior Modification through Pharmacotherapy to Surgery – An Emphasis on the Team Approach
    Scott Isaacs, MD
  • Emerging Concepts of Weight and Energy Regulation
    J. Michael Gonzalez-Campoy, MD,PhD

EDUCATIONAL OBJECTIVES:

  • Examine the role of endocrine systems in the pathophysiology of obesity
  • Understand how weight loss can help ameliorate the endocrine and metabolic abnormalities that that are integral to the disease process
  • Understand how the interaction between excess adiposity and abnormal endocrine and metabolic functioning can inform guidelines and provide rationale for therapeutic approaches.

EDUCATIONAL OBJECTIVES:

  • Review the infrastructure needed for effective obesity care
  • Define a structured approached to chronic obesity care
  • Discuss effective ways to secure a healthy revenue stream for a bariatric endocrinology practice

EDUCATIONAL OBJECTIVES:

  • Understand the physician’s role in obesity management using a multidisciplinary team approach
  • Learn how to choose an initial management strategy for the patient with overweight or obesity
  • Learn how to modify the treatment approach based on available resources

EDUCATIONAL OBJECTIVES:

  • Review recent developments in our understanding of weight regulation
  • Discuss non-hormonal contributors and novel mechanisms of energy balance
  • Practical clinical considerations for your patient today

Room: Suwannee 16/17
CME Code: 9998

 

W32: Bone Disease in 2016: Beyond the Basics
Co-Chairs: Daniel L. Hurley, MD; Rachel Pessah-Pollack, MD

  • Assessing Fracture Risk - The Challenges of DXA and Other Techniques Angelo Licata, MD
  • Hypoparathyroidism: Evolving Therapeutic Options
    Bart L. Clarke, MD
  • Monitoring Postmenopausal Osteoporosis – Which Modalities and How Often?
    Michael R. McClung, MD
  • Beyond Oral Bisphosphonates for Postmenopausal Osteoporosis – Sequential Drug Therapy; What's Next on the Horizon
    Daniel L. Hurley, MD; Rachel Pessah-Pollack, MD

EDUCATIONAL OBJECTIVES:

  • Recognizing problems in clinical use of DXA
  • Understanding the use of vertebral morphology
  • Understanding the pitfalls and benefits of FRAX

EDUCATIONAL OBJECTIVES:

  • Describe the pathogenesis and complications of hypoparathyroidism.
  • Discuss the symptoms of hypoparathyroidism.
  • Summarize currently available and new treatment options for hypoparathyroidism.

EDUCATIONAL OBJECTIVES:

  • Implement an individualized strategy for monitoring response to osteoporosis therapy
  • Apply the recommendations for monitoring during bisphosphonate drug holiday
  • Define treatment failures

EDUCATIONAL OBJECTIVES:

  • Recognize and define the role of sequential drug therapy in treatment of osteoporosis
  • Understand the pathophysiology behind promising new bone treatment agents
  • Identify data regarding the efficacy, risks, and benefits of potential anabolic and antiresorptive agents on the horizon  

Room: Suwannee 18/19
CME Code: 9452

 

W42: AACE – ABIM Maintenance of Certification and Mini - Board Review Course
Chair: Pauline M. Camacho, MD
Speakers: Pauline Camacho, MD; Elise Brett, M; Hossein Gharib, MD; Dace Trence, MD

  • Endocrinology Update 2015
  • Endocrinology Update 2016

EDUCATIONAL OBJECTIVES:

  • To discuss ASAP modules on thyroid and bone
  • To review and discuss the ABIM 2015 Endocrine Updates
  • To review and discuss the ABIM 2016 Endocrine Updates

Room: Suwannee 20/21
CME Code: 8497

5:30 pm - 7:45 pm Satellite Symposia
5:30 pm - 6:00 pm Dinner

5:30 pm – 7:45 pm

WSS1: Hypoparathyroidism: New Treatment Concepts & Guidelines
Room: Suwannee 20/21
CME Code: 8497

5:30 pm – 7:45 pm

WSS2: Concentrated Insulins: Clinical Applications and Use in Practice Settings
Room: Panzacola H3/4
CME Code: 1625

THURSDAY, May 26

5:30 am - 7:30 am Satellite Symposia
5:15 am - 5:45 am Breakfast

5:15 am – 7:30 am

TSS1: LDL-C Reduction in the Patient with Diabetes: How Low Should We Go and How Should We Get There?
Room: Panzacola H 1/2
CME Code: 1575

6:30 am – 6:30 pm

Attendee Registration

7:00 am – 6:00 pm

CME Station Hours

9:45 am -2:15 pm

Exhibit Hall Hours

8:00 am – 8:30 am

General Session Announcements

8:30 am – 9:15 am

TGS1: Diabetes and the Microbiome
Moderator: George Grunberger, MD
Speaker: Robert E.Ratner, MD

EDUCATIONAL OBJECTIVES:

  • Cite current research findings regarding the relationship of the microbiome as a key component of metabolic and immunological function.
  • Discuss the link between the microbiome and the development of autoimmunity
  • Assess the composition of gut microflora associated with complications of inflammatory disease, obesity, and diabetes.

Room: Panzacola F/G
CME Code: 5331

9:15 am – 10:00 am

TGS2: Metabolomics for the Clinician: Implications for the Treatment of Metabolic Disease
Moderator: Derek LeRoith, MD
Speaker: Christopher B. Newgard, PhD

EDUCATIONAL OBJECTIVES:

  • Define the term "metabolomics"
  • Understand how metabolomics is applied to human disease populations
  • Understand examples of how metabolomics is used to define new mechanisms and targets

Room: Panzacola F/G
CME Code: 8024

10:00 am – 11:00 am

Young Investigator Poster Session in Exhibit Hall

10:15 am – 11:00 am

Product Theaters in the Exhibit Hall

11:05 am – 11:15 am

Awards Presentations

11:15 am – 12:00 pm

TGS3: Co-Evolution of Scientific Disciplines and Therapies for Disorders of Lipid Metabolism
Moderator: Jonathan D. Leffert, MD
Speaker: Jay D. Horton, MD

EDUCATIONAL OBJECTIVES:

  • Understand the mechanism of how cholesterol metabolism is regulated
  • Recognize the importance of genetics in the identification of therapeutic targets for hyperlipidemias
  • Understand how PCSK9 inhibitors lower plasma LDL
  • Room: Panzacola F/G
    CME Code: 2893

12:00 pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00 pm – 12:45 pm

Young Investigator ePoster Oral Presentations

12:30 pm – 2:15 pm

Women of Endocrinology Luncheon
Lessons in Leadership: My Path to Presidency (Non-CME)

Moderator: Etie S. Moghissi, MD
Speaker: Pauline M. Camacho, MD

Room: Panzacola H 1/2

1:00 pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm – 2:00 pm

Product Theaters in the Exhibit Hall

2:15 pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

T11: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael D. Holick, MD

EDUCATIONAL OBJECTIVES:

  • Learn how to evaluate and treat vitamin D deficiency
  • Understand the recommendations for vitamin D from the Institute of Medicine and the Endocrine Society
  • Gain an appreciation for the many nonskeletal health benefits of vitamin D

Room: Suwannee 16/17
CME Code: 8253

 

T21: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time Versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: RichardE. Pratley, MD vs. Alan J. Garber, MD

EDUCATIONAL OBJECTIVES:

  • Describe the rationale for selecting initial monotherapy for the treatment of type 2 diabetes
  • Compare efficacy of various treatment options as monotherapy
  • Discuss a strategy for selecting and monitoring initial monotherapy treatment for type 2 diabetes

EDUCATIONAL OBJECTIVES:

  • To understand that the use of multiple agents with complementary actions may facilitate diabetes control
  • To formulate successful strategies to rapidly control hyperglycemia
  • To target the multiple defects of the diabetic state

Room: Suwannee 11/12
CME Code: 7548

T31: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, MD

EDUCATIONAL OBJECTIVES:

  • To understand the prevalence, workup and diagnosis of adrenal incidentalomas
  • To be able to identify the appropriate workup for mild hypercortisolism from adrenal incidentalomas, to understand the sequelae of mild hypercortisolism and to identify the management options
  • To apply that knowledge to patients with adrenal incidentalomas and mild hypercortisolism.

Room: Suwannee 13/14
CME Code: 4915

 

T41: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

EDUCATIONAL OBJECTIVES:

  • To determine the potential risks of very low levels of LDL-C.
  • To discuss whether or not there is a nadir of LDL-C at which additional reduction of CVD risk does not ensue.
  • With PCSK9 therapy, what’s a comfortable reduction for LDL-C

Room: St. John's 24/25
CME Code: 1886

 

T51: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: William D. Zigrang, MD
Speaker: William F. Young Jr., MD

EDUCATIONAL OBJECTIVES:

  • Recognize when to do case detection testing for primary aldosteronism and pheochromocytoma
  • Identify the most common pitfalls in case detection testing for primary aldosteronism and pheochromocytoma
  • Illustrate how to confirm the diagnoses of primary aldosteronism and pheochromocytoma

Room: St. John's 28/29
CME Code: 1354

 

T61: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

EDUCATIONAL OBJECTIVES:

  • Understand causes of short stature
  • Idenifty FDA approved indications for GH treatment
  • Recognize methods of bone age modulation

Room: Suwannee 20/21
CME Code: 3145

 

T71: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: Farhad Zangeneh, MD
Speaker: Michael McDermott, MD

EDUCATIONAL OBJECTIVES:

  • Describe symptoms and signs commonly presented by the pseudo-endocrine patient
  • Review diagnostic evaluations appropriate for the pseudo-endocrine patient
  • Discuss management strategies for the pseudo-endocrine patient

Room: Suwannee 18/19
CME Code: 7336

3:15pm – 3:30pm

Coffee Break

3:30 pm – 4:30 pm

MEET-THE-EXPERTS SESSION II

 

T12: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation
Moderator: M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

EDUCATIONAL OBJECTIVES:

  • Understand treatment options for hypogonadism in men whose fertility status is to be enhanced or preserved
  • Appreciate the risks of direct testosterone therapy in men with infertility
  • Understanding monitoring recommendations for men on treatments for hypogonadism

Room: Suwannee 15
CME Code: 9554

 

T22: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That Is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth B. Ain, MD vs. Ian Hay, MD

EDUCATIONAL OBJECTIVES:

  • Assess the benefits and risks of radioiodine therapy for thyroid carcinoma.
  • Discern the role of radioactive iodine therapy for different prognostic risk groups of thyroid cancer patients.
  • Understand the controversies regarding radioactive iodine therapy in low risk disease

EDUCATIONAL OBJECTIVES:

  • Understand the limitations of diagnostic and therapeutic RAI
  • To better use RAI in a selective fashion
  • To be aware of better alternatives to RAI for scanning and therapy

Room: Suwannee 16/17
CME Code: 1959

 

T32: Is Insulin Therapy Inevitable in the Management of Diabetes?
Moderator: Vivian Fonseca, MD
Speaker: Robert E. Ratner, MD

EDUCATIONAL OBJECTIVES:

  • Describe the traditional natural history of beta cell dysfunction in type 2 diabetes.
  • Review clinical trial data on durability of therapy and interpret findings in relationship to the natural history.
  • Predict the prerequisites to avoiding insulin therapy in type 2 diabetes.

Room: Suwannee 20/21
CME Code: 7264

 

T42: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, M

EDUCATIONAL OBJECTIVES:

  • To understand the prevalence, workup and diagnosis of adrenal incidentalomas
  • To be able to identify the appropriate workup for mild hypercortisolism from adrenal incidentalomas, to understand the sequelae of mild hypercortisolism and to identify the management options
  • To apply that knowledge to patients with adrenal incidentalomas and mild hypercortisolism.

Room: Suwannee 13/14
CME Code: 5304

 

T52: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

EDUCATIONAL OBJECTIVES:

  • To determine the potential risks of very low levels of LDL-C.
  • To discuss whether or not there is a nadir of LDL-C at which additional reduction of CVD risk does not ensue.
  • With PCSK9 therapy, what’s a comfortable reduction for LDL-C

Room: St. John's 24/25
CME Code: 9533

 

T62: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: Farhad Zangeneh, MD
Speaker: William F. Young Jr., MD

EDUCATIONAL OBJECTIVES:

  • Recognize when to do case detection testing for primary aldosteronism and pheochromocytoma
  • Identify the most common pitfalls in case detection testing for primary aldosteronism and pheochromocytoma
  • Illustrate how to confirm the diagnoses of primary aldosteronism and pheochromocytoma

Room: St. John's 28/29
CME Code: 2042

 

T72: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: William D. Zigrang, MD
Speaker: Michael McDermott, MD

EDUCATIONAL OBJECTIVES:

  • Describe symptoms and signs commonly presented by the pseudo-endocrine patient
  • Review diagnostic evaluations appropriate for the pseudo-endocrine patient
  • Discuss management strategies for the pseudo-endocrine patient

Room: Suwannee 18/19
CME Code: 4068

4:30 pm – 4:45 pm

Break

4:45 pm – 5:45 pm

MEET-THE-EXPERTS SESSION III

 

T13: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael F. Holick, MD

EDUCATIONAL OBJECTIVES:

  • Learn how to evaluate and treat vitamin D deficiency
  • Understand the recommendations for vitamin D from the Institute of Medicine and the Endocrine Society
  • Gain an appreciation for the many nonskeletal health benefits of vitamin D

Room: St. John's 24/25
CME Code: 3847

 

T23: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: Richard E. Pratley, MD vs. Alan J. Garber, MD, PhD

EDUCATIONAL OBJECTIVES:

  • Describe the rationale for selecting initial monotherapy for the treatment of type 2 diabetes
  • Compare efficacy of various treatment options as monotherapy
  • Discuss a strategy for selecting and monitoring initial monotherapy treatment for type 2 diabetes

EDUCATIONAL OBJECTIVES:

  • To understand that the use of multiple agents with complementary actions may facilitate diabetes control
  • To formulate successful strategies to rapidly control hyperglycemia
  • To target the multiple defects of the diabetic state

Room: Suwannee 11/12
CME Code: 8878

 

T33: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

EDUCATIONAL OBJECTIVES:

  • Understand causes of short stature
  • Idenifty FDA approved indications for GH treatment
  • Recognize methods of bone age modulation

Room: Suwannee 18/19
CME Code: 8156

 

T43: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation
Moderator:M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

EDUCATIONAL OBJECTIVES:

  • Understand treatment options for hypogonadism in men whose fertility status is to be enhanced or preserved
  • Appreciate the risks of direct testosterone therapy in men with infertility
  • Understanding monitoring recommendations for men on treatments for hypogonadism

Room: Suwannee 15
CME Code: 4926

 

T53: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth Ain, MD vs Ian Hay, MD

EDUCATIONAL OBJECTIVES:

  • Assess the benefits and risks of radioiodine therapy for thyroid carcinoma.
  • Discern the role of radioactive iodine therapy for different prognostic risk groups of thyroid cancer patients.
  • Understand the controversies regarding radioactive iodine therapy in low risk disease

EDUCATIONAL OBJECTIVES

  • Understand the limitations of diagnostic and therapeutic RAI
  • To better use RAI in a selective fashion
  • To be aware of better alternatives to RAI for scanning and therapy

Room: Suwannee 16/17
CME Code: 9985

 

T63: Is Insulin Therapy Inevitable in Management of Diabetes?
Moderator: George Grunberger, MD
Speaker: Robert E. Ratner, MD

EDUCATIONAL OBJECTIVES:

  • Describe the traditional natural history of beta cell dysfunction in type 2 diabetes.
  • Review clinical trial data on durability of therapy and interpret findings in relationship to the natural history.
  • Predict the prerequisites to avoiding insulin therapy in type 2 diabetes.

Room: Suwannee 20/21
CME Code: 7406

 

T73: History of Diabetes Mellitus: 1500 B.C. to Present
Moderator: Chris K. Guerin, MD
Speaker: Philip Levy, MD

EDUCATIONAL OBJECTIVES:

  • Tracing the ancient history of diabetes
  • Discussing the evolution of therapy
  • Looking into the future

Room: Suwannee 13/14
CME Code: 1465

6:00 pm – 7:00 pm

Domestic & International Chapter Receptions

7:15 pm – 9:30pm Satellite Symposia
7:15 pm – 7:45 pm Dinner

7:15 pm – 9:30 pm

TSS3: Balancing the Evidence: Considering the Clinical Impact of Newer Antihyperglycemic Agents for the Treatment of Type 2 Diabetes

Room: Panzacola H 3/4
CME Code: 1284

 

TSS4: Patient Centered Care of the Patient with Obesity

Room: Panzacola H 1/2
CME Code: 1304

FRIDAY, May 26

5:15 am – 7:30 am Satellite Symposia
5:15 am – 5:45 am Breakfast

5:15 am – 7:30 am

FSS1: Keeping Pace with CGM Technology: The Path to Successful Implementation
Room: Panzacola H 1/2
CME Code: 3374

7:30 am – 6:30 pm

Attendee Registration

7:30 am – 6:30 pm

CME Station Hours

9:45 am – 2:15 pm

Exhibit Hall Hours

8:00 am – 8:20 am

Awards Presentation

8:20 am – 9:05 am

FGS1: Pheochromocytoma: Then and Now - A 90-Year Journey
Moderator: Daniel L. Hurley, MD
Speaker: William F. Young Jr., MD

EDUCATIONAL OBJECTIVES:

  • To review the early clinical experience with pheochromocytoma in the 1920s and 1930s
  • To illustrate the key diagnostic and treatment advances over 90 years
  • To provide a wish list agenda for the next decade

Room: Panzacola F/G
CME Code: 7835

9:15 am – 12:00 pm

IN-DEPTH SYMPOSIA SESSION I
MOC Points will be available for select In-Depth Symposia

 

F11: Thryoid Cancer Update
Chair: Hossein Gharib, MD
Supported by the Hossein Gharib, MD Educational Fund

  • Highlights of the ATA Guidelines for Low Risk Differentiated Thyroid Cancer - Histologic and Molecular Approach to Staging
    Erik K. Alexander, MD
  • Ultrasound Follow-up in Papillary Thyroid Cancer and Use of Alcohol Ablation Therapy for Recurrence
    Tara Henrichsen, MD
  • Thyroid Cancer Surgery in 2016
    Julie Ann Sosa , MD
  • Radioactive Iodine Treatment in Thyroid Cancer
    Gregory A. Wiseman, MD

EDUCATIONAL OBJECTIVES:

  • To improve the approach to initial thyroid cancer staging
  • To understand the use of molecular profiling and mutation analysis to guide prognosis and therapy
  • To understand that thyroid cancer risk must be continually reassessed over time

EDUCATIONAL OBJECTIVES:

  • Describe ultrasound protocol for evaluation of the postoperative neck.
  • Recognize ultrasound appearances of recurrent papillary thyroid cancer
  • Describe selection criteria for recurrence suitable for alcohol ablation

EDUCATIONAL OBJECTIVES:

  • To describe the new ATA guidelines for the management of thyroid nodules and differentiated thyroid cancer, focusing on those that apply most to surgeons and surgical practice
  • To assess and evaluate recent evidence in the published literature that supports these new guidelines for the management of differentiated thyroid cancer
  • To illustrate how the new differentiated thyroid cancer guidelines can be applied to practice

EDUCATIONAL OBJECTIVES

  • Learn how to prepare patient for radioiodine whole body scan
  • Learn how to select RAI dose for remnant ablation and metastatic disease
  • Learn safety and complications of RAI Rx

Room: Panzacola H 3/4
CME Code: 1412

 

F21: Endocrine Disorders during Pregnancy
Chair: Felice A.Caldarella, MD

  • Challenging Cases of Thyroid Disease During Pregnancy
    James Hennessey, MD
  • Challenging Cases of Diabetes
    Lois Jovanovic, MD
  • Challenging Cases of Adrenal Disorders
    Deborah P. Merke, MD

EDUCATIONAL OBJECTIVES:

  • Articulate the major thyroid issues encountered in the pregnant woman
  • Expertly evaluate the pregnant patient with thyroid issues to determine etiology
  • Confidently prescribe medications or interventions to appropriately manage thyroid issues in pregnancy

EDUCATIONAL OBJECTIVES:

  • To identify diabetes and pregnancy (hyperglycemia)
  • Understand the goal for treatment
  • Understand the treatment therapy to normalize blood glucose

EDUCATIONAL OBJECTIVES:

  • Know the normal physiological changes in glucocorticoid and mineralocorticoid that occur during pregnancy
  • Describe the presentation of adrenal insufficiency during pregnancy
  • Understand the management of glucocorticoid replacement during pregnancy

Room: Suwannee 13/14
CME Code: 8929

 

F31: AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
Chair: W. Timothy Garvey, MD

  • Anthropometric and Clinical Components to the Diagnosis: Measurement of Adiposity and Impact on Patient Health
    Karl Nadolsky, DO
  • Benefits of Weight Loss Treatment
    Ania Jastreboff, MD
  • The Prescription for Individualized Lifestyle Therapy: Eating Patterns, Evidence and Efficacy
    Daniel L. Hurley, MD
  • A Patient-Centered Approach for the Individualization of Pharmacotherapy
    Jeffrey I. Mechanick, MD
  • Putting it Together: An Evidence-Based Algorithm for Obesity Management
    W. Timothy Garvey, MD

EDUCATIONAL OBJECTIVES:

  • Appreciate obesity as a clinical diagnosis
  • Utilize anthropometric measurements to screen and guide the diagnosis
  • Utilize clinical components beyond anthropometric measurements to diagnose and stage obesity

EDUCATIONAL OBJECTIVES:

  • Understand benefits of weight loss for individuals with obesity
  • Understand rational for therapeutic targets of weight loss
  • Understand therapeutic targets for weight loss specific to the individual

EDUCATIONAL OBJECTIVES:

  • Review the differences in dietary patterns on weight loss
  • Review the efficacy of dietary patterns on cardio-metabolic and other health risks
  • Be aware of motivational interviewing and support groups for successful weight loss

EDUCATIONAL OBJECTIVES:

  • Understand the context of nuance-based pharmacotherapy for obesity
  • Be familiar with specific nuances for many different anti-obesity medications
  • Understand the different mechanisms of action for different anti-obesity medications

EDUCATIONAL OBJECTIVES:

  • Have a working knowledge of the operational aspects of the algorithm for medical care of patients with obesity
  • Understand the grounding of the algorithm in scientific evidence in the context of the clinical practice guidelines.
  • Review how to practically apply the algorithm in real world care venues – i.e., your office

Room: St. John's 24/25
CME Code: 7583

 

F41: Diabetes Update 2016
Chair: Robert R. Henry, MD

  • Role of PCSK9 Inhibitors in Diabetes: Indications for Use and Avoiding Misuse
    Pam R. Taub, MD
  • CV Outcomes Trials in Diabetes: Selected Lessons Learned Thus Far
    Darren McGuire, MD
  • EMPA-REG RESULTS: Implications for CVD Prevention in Type 2 Diabetes
    Robert Eckel, MD
  • Potential Mechanisms for CV Outcome Benefits with Empagliflozin
    Steven E. Nissen, MD
  • SGLT2 Inhibitors and DKA Development: Epidemiology, Pathogenesis and Prevention of DKA in Diabetes
    Lance Sloan, MD

EDUCATIONAL OBJECTIVES:

  • Review mechanisms of PCSK9 in lipid metabolism and glucose homeostasis.
  • Understand the role of PCSK9 inhibitors for secondary prevention of cardiovascular disease.
  • Compare efficacy and side effects of PCKS9 inhibitors with statins in patients with diabetes and metabolic syndrome.

EDUCATIONAL OBJECTIVES:

  • Review the residual risk of cardiovascular disease in diabetes
  • Review the recent history of regulation of drugs for type 2 diabetes
  • Review reported results from completed CV outcomes trials in type 2 diabetes

EDUCATIONAL OBJECTIVES:

  • By what mechanisms did empaglifozin prevent CVD in patients with type 2 diabetes?
  • Was this a SGLT2 class effect or just the molecule empaglifozin?
  • Based on EMPA-REG results, should my choices of glucose-lowering therapies for type 2 diabetes change?

EDUCATIONAL OBJECTIVES:

  • Discuss history of cardiovascular outcomes trials for diabetes drugs
  • Discuss cardiovascular effects of SGLT2 inhibition
  • Discuss which mechanism(s) of drug effect are most likely responsible for CV benefits observed

EDUCATIONAL OBJECTIVES:

  • Be familiar with the evidence behind SGLT2i: use and development of DKA
  • Understand the pathophysiology behind SGLT2i: use and the development of DKA
  • How to appropriately use SGLT2i without the development of DKA
Room: Suwannee 11/12
CME Code: 2398

 

F51: Practical Clinical Guide to Endocrine Diseases for Nurse Practitioners/ Physician Assistants
Chairs: W. Reid Litchfield, MD; Sondra O’ Callaghan, PA

  • Diabetes Mellitus, Obesity and Hyperlipidemia
    Israel Hartman, MD
  • Clinical Pearls for the Evaluation and Treatment of Thyroid Disorders
    W. Reid Litchfield, MD
  • Screening for Common Adrenal, Pituitary, and Reproductive Diseases
    Richard Auchus, MD
  • Calcium/Bone Disorders
    Steven M. Petak, MD

EDUCATIONAL OBJECTIVES:

  • Review current knowledge on the pathophysiology
  • Review current knowledge on the management
  • Review current guidelines

EDUCATIONAL OBJECTIVES:

  • Understand the differential diagnosis of thyrotoxicosis and initiate an appropriate diagnostic workup for thyrotoxicosis
  • Review risks and common pitfalls associated with thionamide therapy for hyperthyroidism
  • Develop a diagnostic approach to nodular thyroid disease and recognize indicators of higher-risk thyroid nodules

EDUCATIONAL OBJECTIVES:

  • To identify patients who should be screened for primary aldosteronism and the proper screening procedure.
  • To list the screening tests for deficiency or excess of each pituitary hormone.
  • To describe the initial steps in the evaluation of amenorrhea.

EDUCATIONAL OBJECTIVES:

  • Describe the approach to the evaluation of osteoporosis and metabolic bone disease
  • Recognize the application and pitfalls of Bone Densitometry
  • Apply a logical approach to therapy of osteoporosis

Room: Suwannee 20/21
CME Code: 8505

10:00 am – 12:00 pm

F61: Novel Developments in Diabetes Technology (Non-CME)
Moderators: Timothy Bailey, MD; Alan Garber, MD; R. Mack Harrell, MD

  • Progress Toward Closed Loop Systems
    Scott W. Lee, MD
  • Progress Toward the Bionic Pancreas
    Edward Damiano, PhD

EDUCATIONAL OBJECTIVES:

  • Understand the step wise progression of innovations in insulin suspension and hybrid closed loop technology
  • Review medical literature and recent studies for closed loop technology
  • Clinical applications of hybrid closed loop technology

EDUCATIONAL OBJECTIVES:

  • Recognize the challenges that must be met to automate control of blood glucose levels in people with type 1 diabetes
  • List the elements of an automated closed-loop bionic pancreas
  • Describe the results of a recent clinical study of closed-loop blood glucose control using subcutaneous delivery of insulin and glucagon

Room: Suwannee 18/19

12:00 pm – 2:15 pm

Exhibit Hall Break

12:00 pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00 pm – 12:45 pm

ePoster Oral Presentations

12:30 pm – 2:15 pm

FIT Luncheon

1:00 pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm – 2:00 pm

Product Theaters in the Exhibit Hall

2:15 pm – 5:00 pm

IN-DEPTH SYMPOSIA SESSION II
MOC Points will be available for select In-Depth Symposia

 

F12: A Tribute to Saul Hertz: 75th Anniversary of the Use of Radioactive Iodine
Chair: Jeffrey R. Garber, MD; Lewis E. Braverman, MD

  • 131 Iodine Therapy: A Brief History
    Lewis E. Braverman, MD
  • The Sodium/Iodide Symporter (NIS): From Patient to Molecule and Back
    Nancy Carrasco, MD
  • Diagnostic and Therapeutic Uses of Radioactive Iodine
    Douglas Van Nostrand, MD
  • Targeted Approaches for Enhancing RAI Avidity in Thyroid Cancer
    Alan Ho, MD

EDUCATIONAL OBJECTIVES:

  • Learn about the early contributions of Saul Hertz
  • Understand the conflicts related to the use of I31I in the early days
  • Learn about the modern science of the use of I31I as discussed y the next 3 speakers

EDUCATIONAL OBJECTIVES:

  • To elucidate the physiological role of the sodium/iodide symporter (NIS) and its expression and regulation in different tissues.
  • To explain how the investigation at the molecular level of mutations in NIS found in patients has been extremely instructive in enabling us to uncover unexpected properties of NIS, some of great medical relevance.
  • To describe clinical applications of NIS beyond thyroid disease, both in tissues and cancers in which NIS is endogenously expressed and in those in which it is not endogenously expressed but can be expressed using gene transfer methods.

EDUCATIONAL OBJECTIVES:

  • To list techniques to obtain higher resolution radioiodine imaging that can affect management of patients with differentiated thyroid cancer,
  • To described recent advance in imaging technology including SPECT and PET,
  • To list advances in determining radioiodine prescribed activity for treatment of differentiated thyroid cancer, and
  • To discuss simplified dosimetry that can be performed in any nuclear medicine facility.

EDUCATIONAL OBJECTIVES:

  • Describe the central biologic drivers of follicular-cell derived thyroid cancers.
  • Discuss the potential benefits and limitations of RAI therapy in various stages of thyroid cancer management.
  • Describe and evaluate experimental efforts centered on using targeted therapies to enhance RAI avidity in thyroid cancer.

Room: Suwannee 15
CME Code: 9758

 

F22: Transgender Medicine: What an Endocrinologist Should Know
Chair: Vin Tangpricha, MD

  • How to Treat Adolescents with Transgender Identity
    Stephen M. Rosenthal, MD
  • Standards of Care in the Diagnosis of Gender Dysphoria
    Eli Coleman, PhD
  • Guidelines for the Clinical Care of Persons with Gender Dysphoria
    Wylie Hembree, MD
  • Sex Reassignment Surgery
    Stan Monstrey, MD

EDUCATIONAL OBJECTIVES:

  • Describe basic elements of the diagnostic criteria for gender dysphoria
  • Know the current criteria for administering cross-sex hormones to trans patients
  • Describe the main roles for the endocrinologist in treating gender dysphoric patients

EDUCATIONAL OBJECTIVES:

  • Understand the clinical basis of the Endocrine Treatment of Gender Dysphoria
  • Follow the Principles of Endocrine Protocols Used in Treatment of Gender Dysphoria
  • Understand Social, Legal and Ethical Aspects of Clinical Care of Gender Dysphoria

EDUCATIONAL OBJECTIVES:

  • To provide insight on illegibility and readiness criteria for sex reassignment surgery
  • To give an overview of surgical interventions for female-to-male transsexual individuals
  • To give an overview of surgical interventions for male-to-female transsexual individuals

EDUCATIONAL OBJECTIVES:

  • Understand current concepts of the biology of gender identity development.
  • Understand use of pubertal blockers and cross sex hormones in management of gender dysphoric/transgender youth.
  • Understand limitations and barriers to care of transgender youth, gaps in knowledge, and priorities for research.

Room: Suwannee 11/12
CME Code: 9137

 

F32: Endocrinology and Aging, or, “The Taper”
Chair: Peter A. Singer, MD

  • Muscle Loss and Aging - Even Arnold has Sarcopenia
    John Morley, MBBCh
  • Does Growth Hormone Keep You Younger?
    Shlomo Melmed, MD
  • Men Getting Older - Will Testosterone Keep Him Younger?
    Alvin Matsumoto, MD
  • Women Getting Older - and Even Better
    Holly L. Thacker, MD
  • Thyroid Disorders in “Oldsters”: Its Ups and Downs
    Stephanie Lee, MD

EDUCATIONAL OBJECTIVES:

  • To recognize the importance of identifying frailty in patients using the simple FRAIL screening tool and the best treatment options for older adults
  • To recognize and know the treatments for sarcopenia as well as to be aware of the emerging treatments now available
  • To recognize the importance of accelerated sarcopenia in persons with diabetes

EDUCATIONAL OBJECTIVES:

  • Understand the physiology of human GH secretion and how it changes with aging
  • Assess the risks and benefits of inappropriate GH administration to elderly frail patients
  • Understand the adverse effects of GH on metabolic, cardiovascular and cell replicative functions.

EDUCATIONAL OBJECTIVES:

  • Improve the accuracy of diagnosing male hypogonadism in order to avoid potential over-diagnosis and over-treatment with testosterone
  • Identify functional causes of secondary hypogonadism that may be reversible ro treatable without testosterone
  • Integrate consideration of the contribution of comorbidities and/or medications to clinical manifestations attributable to androgen deficiency during T treatment

EDUCATIONAL OBJECTIVES:

  • Review guidelines for treating menopause
  • Discuss hormone and non-hormone therapies
  • Discuss newer therapies for midlife women

EDUCATIONAL OBJECTIVES:

  • Aging and increase risk of incidental nodules: how to detect malignancy?
  • Define what is the normal TSH in the healthy aging individual?
  • Should subclinical hypothyroidsm in the aging population be treated with levothryoxine?

Room: Panzacola H 3/4
CME Code: 2266

 

F42: Neuroendocrine Tumor (NET) Syndromes
Chair: Aaron I. Vinik, MD

  • Update on Pheochromocytoma and Paraganglioma: Implications for Clinical Practice
    Karel Pacak, MD
  • Peptide Receptor Radio-Nuclide Therapy as a Novel, Rationale Option of Care for Metastatic NETs
    Tom O’Dorisio, MD
  • Results of New Clinical Trials and Implications for Therapy of NETS
    Matt Kulke, MD
  • Update on Surgical Management of NETS
    James Howe, MD

EDUCATIONAL OBJECTIVES:

  • Educate about newest genetic discoveries of pheochromocytoma and paraganglioma
  • Educate about newest biochemical and imaging strategies to diagnose and localize pheochromocytoma and parganglioma
  • Educate about current therapeutic approaches to pheochromocytoma and paraganglioma

EDUCATIONAL OBJECTIVES:

  • To appreciate the peptide-membrane receptor kinetic inherent for both diagnostic and therapeutic application in neuroendocrine tumor therapy.
  • To understand the rationale of peptide-receptor radionuclide therapy (PRRNT) as an important therapeutic option for patients with metastatic neuroendocrine tumors.

EDUCATIONAL OBJECTIVES:

  • Describe current systemic therapy for neuroendocrine tumors
  • Describe and analyze results of recent clinical trials of novel sysyemtic therapy
  • Integrate results of recent clinical trials into the current treatment paradigm for neuroendocrine tumors or neuroendocrine tumors

EDUCATIONAL OBJECTIVES:

  • Learn the most common types of GI NETS
  • Review the work-up of small bowel and pancreatic NETs
  • Discuss role of removal of primary and hepatic debulking in metastatic NETs

Room: Suwannee 16/17
CME Code: 1040

 

F52: 8th AACE/SMNE Joint Session: Reflections and Future Directions in Endocrinology
(presented in Spanish)
Co-Chairs: Myriam Allende-Vigo, MD & Miguel A. Madero, MD

  • The Mexican Acromegaly Registry: An In-Depth Analysis of the Epidemiology of the Disease
    Moises Mercado, MD
  • Role of Magnesium in the Impaired Glucose Metabolism
    Fernando Guerrero Romero, MD
  • The Last 25 Years has Changed Diabetes from A to Z
    Jaime Davidson, MD
  • Update in Thyroid Cancer
    Maria Cabanillas, MD

EDUCATIONAL OBJECTIVES:

  • To learn the basic epidemiological features of acromegaly in LA
  • To understand how resources availability affect the morbidity and mortality of the disease
  • To ascertain the efficacy of the different therapeutic options in a real-life scenario

EDUCATIONAL OBJECTIVES:

  • To establish te role of magnesium on the risk of developing glucose metabolic disorders
  • To review evidence regarding benefits of magnesium supplementation as adjuvant therapy for type 2 diabetes
  • To review evidence regarding efficacy of magnesium supplementation in the prevention of type 2 diabetes

EDUCATIONAL OBJECTIVES:

  • Recognize that Diabetes pathophysiology has changed dramatically since AACE first annual meeting
  • Describe the incidence and prevalence of diabetes today that was not predicted 25 years ago.
  • Contrast the old and the new treatments.Today based on the new pathophysiology the treatment has evolved and AACE has been in the forefront of algorithms and recommendations

EDUCATIONAL OBJECTIVES:

  • To review the management of early stage thyroid carcinoma
  • To review the management of late stage thyroid carcinoma
  • Review cutting edge clinical research in thyroid carcinoma

Room: Suwannee 18/19
CME Code: 9910

 

F62: The Future of Endocrinology Reimbursement
Co-Chairs: Katherine Roberts, MD; Howard Lando, MD

  • Opting out of Medicare
    Katherine Roberts, MD
  • Merit-Based Incentive Payment System (MIPS) and Medicare Access & CHIP Reauthorization Act of 2015(MACRA): Making Sense of the New Regulations
    Jill Rathbun, MD
  • Creating a New Business Model For Endocrinology: The ACO and the Endocrinologist
    William Biggs, MD
  • Informatics 2016: How Do We Get from Meaningful Use to Precision Medicine?
    Douglas Fridsma, MD

EDUCATIONAL OBJECTIVES:

  • Demonstrate why physicians would benefit from Opting Out of Medicare
  • Demonstrate which physicians should consider Opting Out of Medicare
  • Demonstrate the paperwork involved in Opting Out of Medicare

EDUCATIONAL OBJECTIVES:

  • Define all the new requirements and choices for physicians of the Medicare Access and CHIP Reauthorization Act of 2015. We will identify what the new payment system starting in 2019 for Medicare for physicians entails and the choices physicians will have to make.
  • Identification of the elements of the Merit Incentive Payment System and what is available for AACE members who are interested in participating in this under Medicare. Identification of different alternative payment models and how their design could be applicable to the practice of endocrinology.
  • Relate how these changes can be handled at the practice level and what tools/supports AACE is working on for its members.

EDUCATIONAL OBJECTIVES:

  • Describe how clinical integration of practices might improve care, and ACO 'superpowers'
  • Recognize how to make yourself valuable to ACO, and how diagnosis coding affects your value
  • Discuss strategies when selecting and contracting with ACOs

EDUCATIONAL OBJECTIVES:

  • Understand the historical context of HITECH act, and the implications of this on the current state of EHRs
  • Describe the characteristics of the one ultra-large scale system, the two parts of the definition of interoperability, the triple aim, the four scales of community engagement and the five building blocks of standards
  • Describe the near-term solutions to improve EHRs and anticipate future trends and their impact on informatics and health IT

Room: Suwannee 20/21
CME Code: 1073

5:00 pm – 6:15 pm

Poster Session in Exhibit Hall

5:00 pm – 6:30 pm

Wine & Cheese Reception in Exhibit Hall

6:15 pm – 7:00 pm

Product Theaters in the Exhibit Hall

7:00 pm – 9:15 pm Satellite Symposia
7:00 pm – 7:30 pm Dinner

7:00 pm – 9:15 pm

FSS3: Basal Insulin 4.0: Updating Your Clinical Practice with Ultralong-acting Insulins

Room: Panzacola H 1/2
CME Code: 6224

7:00 pm – 9:15 pm

FSS4: Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options

Room: Panzacola H 3/4
CME Code: 1809

SATURDAY, May 28

7:30 am – 5:00 pm

Attendee Registration

7:00 am – 6:00 pm

CME Station Hours

9:45 am -2:15 pm

Exhibit Hall Hours

8:00 am – 8:15 am

Award Presentations

8:15 am – 9:00 am

SGS1: The Role of Molecular Markers in Thyroid Nodule Management:Then and Now
Moderator: Hossein Gharib, MD
Speaker:Yuri Nikiforov, MD

EDUCATIONAL OBJECTIVES:

  • To provide an overview of molecular alterations in thyroid tumors.
  • To discuss diagnostic utility of molecular markers for thyroid nodules and cancer.
  • To discuss prognostic utility of molecular markers for risk stratification of thyroid cancer.


Room: Panzacola F/G
CME Code: 3245

9:00 am – 9:15 am

Award Presentations

9:15 am – 10:00 am

SGS2: The Obesity Epidemic, A Public Health Emergency?
Moderator: Yank Coble, MD
Speaker: Regina Benjamin, MD

EDUCATIONAL OBJECTIVES:

  • have a historical perspective of the last 25 years of Obesity
  • have a perspective of the future public health consequences of Obesity
  • How you can Make a Difference


Room: Panzacola F/G
CME Code: 3103

 

SGS3: Select Abstract Oral Presentations I
Moderator: S. Sethu Reddy, MD

THE PREVALENCE OF FASTING-EVOKED EN-ROUTE HYPOGLYCEMIA IN DIABETES (FEEHD) IN CLINICAL PRACTICE: A PILOT SURVEY
Saleh Aldasouqi, MD

CONTEMPLATING AN ADDITIONAL ORAL AGENT FOR YOUR PATIENT WITH TYPE 2 DIABETES? CONSIDER POSSIBLE INTERACTION BETWEEN QUALITY OF YOUR CONVERSATION WITH PATIENT’S ATTEMPTS AT BARGAINING AND SELF-REPORTED OUTCOMES - LESSONS FROM THE INTRODIA™ STUDY
Leo Seman, MD

A RANDOMIZED CONTROL TRIAL ON REDUCTION OF HEMOGLOBIN A1C USING CELL PHONES, COMMUNITY HEALTH WORKERS OR COMBINATION OF BOTH IN A DISTRICT OF COLUMBIA AFRICAN AMERICAN POPULATION
Nesreen Hagahmed, MBBS

EDUCATIONAL OBJECTIVES:

  • To describe a newly described form of hypoglycemia that is associated with fasting for lab tests
  • To discuss the controversy of fasting for lipid tests with a call to eliminate the fasting prerequisite in view of the support of compelling evidence
  • To increase awareness among clinicians about FEEHD in an effort to prevent its occurrence.

EDUCATIONAL OBJECTIVES:

  • Discuss how patients defer additional diabetes treatments
  • Discuss what makes the addition of new medications acceptable to patients
  • Describe a regional difference

EDUCATIONAL OBJECTIVES:

  • To compare the effectiveness of A1c reduction after 3 months using cell phone text reminders, community health workers or the combination of both on a predominately African American District of Columbia Medicaid population
  • To determine if addition of mobile health systems and/or community health workers can improve diabetes self-management skills
  • Identify effective interventions that may improve diabetes control

Room: Panzacola H 1/2
CME Code: 6849

 

SGS4: Select Abstract Oral Presentations II
Moderator: David Lieb, MD

SYSTEMATIC REVIEW OF THE POSITIVE PREDICTIVE VALUE OF RAS MUTATIONS IN CYTOLOGICALLY INDETERMINATE THYROID NODULES
Mark Lupo, MD

RADIOFREQUENCY ABLATION: AN INNOVATIVE TREATMENT FOR ADRENAL NEOPLASMS
Lima Lawrence, MD

USE OF A DIGITAL HEALTH OFFERING TO OPTIMIZE STATIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES
Juan Frias, MD, FACE

EDUCATIONAL OBJECTIVES:

  • Review the reported PPV of a RAS mutation in nodules that are cytologically indeterminate
  • Explore differences in histologic malignancy rates when pathologists are blinded and unblinded to FNA mutation results of RAS positivity
  • Discuss clinical management and surgical decision making for patients with cytologically indeterminate, RAS positive thyroid nodules

EDUCATIONAL OBJECTIVES:

  • Recognize radiofrequency ablation as an alternative to surgery for adrenal neoplasms
  • Identify patients who may benefit from radiofrequency ablation of adrenal neoplasms
  • Consider referring appropriate patients for radiofrequency ablation of adrenal neoplasms

EDUCATIONAL OBJECTIVES:

  • Better understand the importance of medication compliance and adherence in the treatment of patients with chronic diseases
  • Become familiar with the Proteus digital health offering
  • Better understand how patient and HCP engagement using digital health offerings may improve medication adherence


Room: Panzacola H 3/4
CME Code: 8071

10:00 am – 11:00 am

Late Breaking Poster Session in Exhibit Hall

10:15 am – 11:00 am

Product Theaters in the Exhibit Hall

11:00 am – 11:15 am

Award Presentations

11:15 am – 12:00 pm

SGS5: Osteoporosis Drugs: Then and Now
Moderator: Pauline M. Camacho, MD
Speaker: Michael R. McClung, MD

EDUCATIONAL OBJECTIVES:

  • Summarize the effectiveness and limitations of current treatments
  • Interpret the results of studies evaluating the skeletal effects of inhibiting cathepsin K
  • Explain the treatment effects of inhibiting sclerostin activity

Room: Panzacola F/G
CME Code: 4744

11:15 am – 12:15 pm

SGS6: Late Breaking Oral Presentations (Non-CME)
Moderators: S. Sethu Reddy, MD; David C. Lieb, MD

Room: Panzacola H 1/2

12:00 pm – 2:15 pm Exhibit Hall Open

12:15 pm – 2:00 pm

AACE Annual Business Meeting Luncheon

2:15 pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

S11: Treatment of Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy, MD

EDUCATIONAL OBJECTIVES:

  • Define severe obesity in the pediatric population
  • Identify Co-Morbidities associated with pediatric obesity
  • Discuss the available therapies and the role of bariatric surgery in pediatric obesity

Room: Suwannee 20/21
CME Code: 1741

 

S21: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Ved V. Gossain, MD
Speaker: Henry G. Bone III, MD

EDUCATIONAL OBJECTIVES:

  • The participant will recognize the radiographic appearance of Paget's Disease of Bone, as well as the typical biochemical markers of disease activity
  • The participant will recognize the major complications of Paget's Disease of Bone and their management
  • The participant will be able to formulate a treatment plan that will take into account contributory disorders, disease severity, extent and activity, as well as surveillance for recurrence or incomplete response

Room: St. John's 28/29
CME Code: 1429

 

S31: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator:Kathleen Wyne, MD
Speaker: S. Mitchell Harman, MD

EDUCATIONAL OBJECTIVES:

  • Critically evaluate the outcomes and conclusions of the WHI trial
  • Appreciate and integrate new data from trials of menopausal hormone replacement subsequent to the WHI
  • Better individualize advice on hormone therapy to menopausal patients based on individual risk factors and preferences

Room: Suwannee 16/17
CME Code: 3734

 

S41: Diagnosis and Management of Anabolic Steroid Abuse
Moderator: Sri Prakash Mokshagundam,MD
Speaker: Darius A. Paduch, MD

EDUCATIONAL OBJECTIVES:

  • Identify difference between anabolic steroids, therapeutic use and abuse. Recognize complex interaction between psychological, social and genetic factors as a risk for anabolic steroid abuse.
  • Integrate knowledge of physiology and pharmacology with patients’ immediate and long-term goals. Interpret laboratory results to differentiate between secondary effects of anabolic steroid abuse from potential pathological situations.
  • Formulate patient’s goals specific treatment, follow up and surveillance plan to avoid relapse and reverse long term endocrinological, psychological and metabolic effects of anabolic steroid abuse.

Room: Suwannee 15
CME Code: 8320

 

S51: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Sandra L. Weber, MD
Speaker: Stephanie Lee, MD

EDUCATIONAL OBJECTIVES:

  • Define the characteristics of a "benign" thyroid nodule
  • Review risk of cancer of "benign" thyroid nodules
  • Long term management of "benign" thyroid nodules: when can we stop watchful waiting?

Room: St John's 24/25
CME Code: 6429

 

S61: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A. Trager,MD
Speaker: Juan P. Brito, MD

EDUCATIONAL OBJECTIVES:

  • To describe the benefits and harms of active surveillance and thyroid surgery for low risk thyroid cancer
  • To identify the ideal candidates for active surveillance for low risk thyroid cancer
  • To use a decision aid to help clinicians and patients make a treatment decision for low risk thyroid cancer

Room: Suwannee 13/14
CME Code: 1901

 

S71: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S.H. Bell, MD
Speaker: Joseph G. Verbalis, MD

EDUCATIONAL OBJECTIVES:

  • Understand the differential diagnosis of hyponatremic disorders, and particularly the criteria for diagnosing the syndrome of inappropriate antidiuretic hormone section (SIADH).
  • Understand current guidelines for therapy hyponatremia, and how these differ depending on the etiology of the disorder, the duration of the disorder, and the presence of neurological symptoms.
  • Understand the pathogenesis of osmotic demyelination and the implications this has for how rapidly hyponatremia can be safely corrected.

Room: Suwannee 11/12
CME Code: 2819

 

S81: Approach to the Transgender Adolescent: The Evaluation
Moderator: Vin Tangpricha, MD
Speaker: Stephen M. Rosenthal, MD

EDUCATIONAL OBJECTIVES:

  • Understand current concepts of the biology of gender identity development.
  • Understand use of pubertal blockers and cross sex hormones in management of gender dysphoric/transgender youth.
  • Understand limitations and barriers to care of transgender youth, gaps in knowledge, and priorities for research

Room: Suwannee 18/19
CME Code: 3838

3:15pm – 3:30pm

Coffee Break

3:30 pm – 4:30 pm

MEET-THE-EXPERTS SESSION II

 

S12: Challenging Pituitary Cases
Moderator: Anne L. Leddy, MD
Speaker: Eliza B. Geer, MD

EDUCATIONAL OBJECTIVES:

  • Diagnose and localize Cushing's disease
  • Treat challenging acromegaly cases
  • Manage aggressive pituitary tumors

Room: Suwannee 16/17
CME Code: 4222

 

S22: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Dace Trence, MD
Speaker: Bart L. Clarke, MD

EDUCATIONAL OBJECTIVES:

  • Describe the pathogenesis and complications of hypoparathyroidism.
  • Discuss the symptoms of hypoparathyroidism.
  • Summarize currently available and new treatment options for hypoparathyroidism.

Room: Suwanee 20/21
CME Code: 4887

 

S32: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD; Vin Tangpricha,MD
Case Study: The Jennings Family (“I am Jazz”)

EDUCATIONAL OBJECTIVES:

  • Understand current concepts of the biology of gender identity development.
  • Understand use of pubertal blockers and cross sex hormones in management of gender dysphoric/transgender youth.
  • Understand limitations and barriers to care of transgender youth, gaps in knowledge, and priorities for research


Room: Suwannee 18/19
CME Code: 4907

 

S42: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A. Trager, MD
Speaker: Juan P. Brito, MD

EDUCATIONAL OBJECTIVES:

  • To describe the benefits and harms of active surveillance and thyroid surgery for low risk thyroid cancer
  • To identify the ideal candidates for active surveillance for low risk thyroid cancer
  • To use a decision aid to help clinicians and patients make a treatment decision for low risk thyroid cancer

Room: Suwannee 13/14
CME Code: 9250

 

S52: Diagnosis and Management of Anabolic Steroid Abuse
Moderator: Sri Prakash Mokshagundam,MD
Speaker: Darius Paduch, MD

EDUCATIONAL OBJECTIVES:

  • Identify difference between anabolic steroids, therapeutic use and abuse. Recognize complex interaction between psychological, social and genetic factors as a risk for anabolic steroid abuse.
  • Integrate knowledge of physiology and pharmacology with patients’ immediate and long-term goals. Interpret laboratory results to differentiate between secondary effects of anabolic steroid abuse from potential pathological situations.
  • Formulate patient’s goals specific treatment, follow up and surveillance plan to avoid relapse and reverse long term endocrinological, psychological and metabolic effects of anabolic steroid abuse.

Room: Suwannee 15
CME Code: 7699

 

S62: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Elise Brett, MD
Speaker: Stephanie Lee, MD

EDUCATIONAL OBJECTIVES:

  • Define the characteristics of a "benign" thyroid nodule
  • Review risk of cancer of "benign" thyroid nodules
  • Long term management of "benign" thyroid nodules: when can we stop watchful waiting?

Room: St. John's 24/25
CME Code: 3718

 

S72: Osteoporosis Drug Holidays: Why, When and What's After
Moderator: Victor L. Roberts, MD
Speaker: Paul D. Miller, MD

EDUCATIONAL OBJECTIVES:

  • Understand Bisphosphate / D Mab Pharmacology
  • Understand Patient Selection for "Drug Holiday"
  • Consider what to do "post" drug holiday

Room: St. John's 28/29
CME Code: 4714

 

S82: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S.H. Bell, MD
Speaker: Joseph G. Verbalis, MD

EDUCATIONAL OBJECTIVES:

  • Understand the differential diagnosis of hyponatremic disorders, and particularly the criteria for diagnosing the syndrome of inappropriate antidiuretic hormone section (SIADH).
  • Understand current guidelines for therapy hyponatremia, and how these differ depending on the etiology of the disorder, the duration of the disorder, and the presence of neurological symptoms.
  • Understand the pathogenesis of osmotic demyelination and the implications this has for how rapidly hyponatremia can be safely corrected.

Room: Suwannee 11/12
CME Code: 5867

4:30 pm – 4:45 pm

Break

4:45 pm – 5:45 pm

MEET-THE-EXPERTS SESSION III

 

S13: Treatment of Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy, MD

EDUCATIONAL OBJECTIVES:

  • Define severe obesity in the pediatric population
  • Identify Co-Morbidities associated with pediatric obesity
  • Discuss the available therapies and the role of bariatric surgery in pediatric obesity

Room: Suwannee 15
CME Code: 9405

 

S23: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator: Rhoda H. Cobin, MD
Speaker: S. Mitchell Harman, MD

EDUCATIONAL OBJECTIVES:

  • Critically evaluate the outcomes and conclusions of the WHI trial
  • Appreciate and integrate new data from trials of menopausal hormone replacement subsequent to the WHI
  • Better individualize advice on hormone therapy to menopausal patients based on individual risk factors and preferences

Room: St. John's 24/25
CME Code: 9365

 

S33: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Gary W. Edelson, MD
Speaker: Henry G.Bone III, MD

EDUCATIONAL OBJECTIVES:

  • The participant will recognize the radiographic appearance of Paget's Disease of Bone, as well as the typical biochemical markers of disease activity
  • The participant will recognize the major complications of Paget's Disease of Bone and their management
  • The participant will be able to formulate a treatment plan that will take into account contributory disorders, disease severity, extent and activity, as well as surveillance for recurrence or incomplete response

Room: Suwannee 11/12
CME Code: 1235

 

S43: Challenging Pituitary Cases
Moderator: Alex Tessnow, MD
Speaker: Eliza Geer, MD

EDUCATIONAL OBJECTIVES:

  • Diagnose and localize Cushing's disease
  • Treat challenging acromegaly cases
  • Manage aggressive pituitary tumors

Room: Suwannee 16/17
CME Code: 7716

 

S53: Osteoporosis - Drug Holidays: Why, When and What's After
Moderator: Paul V. Tomasic, MD
Speaker: Paul D. Miller, MD

EDUCATIONAL OBJECTIVES:

  • Understand Bisphosphate / D Mab pharmacology
  • Understand Patient Selection for "Drug Holiday"
  • Consider what to do "post" drug holiday

Room: St. John's 28/29
CME Code: 6711

 

S63: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Donald A. Bergman, MD
Speaker: Bart L. Clarke, MD

EDUCATIONAL OBJECTIVES:

  • Describe the pathogenesis and complications of hypoparathyroidism.
  • Discuss the symptoms of hypoparathyroidism.
  • Summarize currently available and new treatment options for hypoparathyroidism.

Room: Suwannee 20/21
CME Code: 9542

 

S73: Medicine After the Holocaust
Moderator: Richard S. Rosenthal, MD
Speaker: Sheldon Rubenfeld, MD

EDUCATIONAL OBJECTIVES:

  • Describe the critical role of German physicians in the design and implementation of the Holocaust.
  • Recognize the moral, legal, and philanthropic support of German eugenics by American eugenicists.
  • Debate the implications of medicine during the Third Reich for contemporary medical practice and research.

Room: Suwannee 13/14
CME Code: 9817

 

S83: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD
Case Study: The Jennings Family (“I am Jazz”)

EDUCATIONAL OBJECTIVES:

  • Understand current concepts of the biology of gender identity development.
  • Understand use of pubertal blockers and cross sex hormones in management of gender dysphoric/transgender youth.
  • Understand limitations and barriers to care of transgender youth, gaps in knowledge, and priorities for research

Room: Suwannee 18/19
CME Code: 9648

6:30 pm

ACE Convocation

7:30 pm

President’s Gala

SUNDAY, May 29

7:00 am – 11:00 am

Attendee Registration

7:00 am - 8:00 am

Attendee Breakfast
Room: Panzacola F/G

7:30 am – 12:00 pm

CME Station Hours

8:00 am – 8:15 am

General Session Announcements

8:15 am – 8:45 am

SGS8: Controversies in the Approach to Adrenal Nodules
Moderator: Antonia E. Stephen, MD
Panel: Karel Pacak, MD, Antonia E. Stephen, MD; Peter M. Sadow, MD

EDUCATIONAL OBJECTIVES:

  • Define the anatomy, physiology, and pathophysiology of the adrenal glands, and understand the different types of adrenal tumors that may require surgery.
  • Describe the recommended biochemical and radiologic work-up for an incidentally discovered adrenal mass.
  • Understand the important steps in a laparoscopic adrenalectomy, including the possible pitfalls and complications.

Room: Panzacola F/G
CME Code: 7017

8:45 am – 9:30 am

SGS9: The Mystery of the Hidden Parathyroid Adenoma
Moderator: Jennifer L. Marti, MD
Panel: Azeez Farooki, MD; Peter M. Sadow, MD

EDUCATIONAL OBJECTIVES:

  • Discuss surgical indications for primary hyperparathyroidism
  • Discuss options for parathyroid adenoma localization
  • Recommend advice on challenging parathyroid cases

Room: Panzacola F/G
CME Code: 5418

9:30 am – 9:45 am

Coffee Break

9:45 am – 11:00 am

SGS7: Dilemmas in Thyroid Cancer: Endocrine/Surgical Consensus
Moderator: Gregory W. Randolph, MD
Speaker: Peter A. Singer, MD, Gregory W. Randolph, MD; Peter M. Sadow, MD

EDUCATIONAL OBJECTIVES:

  • To review the importance of preop laryngeal exam
  • To discuss neural monitoring in thyroid surgery
  • To discuss outcome analysis of laryngeal function after thyroid surgery

Room: Panzacola F/G
CME Code: 1043

11:00 am – 11:15 am

Final Announcements; Adjournment